Biohaven Ltd.

Biohaven Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing treatments for immunology, neuroscience, and oncology. Its pipeline includes BHV-1300 for Graves' disease and rheumatoid arthritis (Phase 2), BHV-1400 for IgA nephropathy (Phase 2), BHV-1600 for peripartum cardiomyopathy (Phase 1), BHV-8000 for Parkinson's disease (Phase 3), Opakalim for focal epilepsy (Phase 3), BHV-2100 for pain disorders (Phase 2), BHV-2000 for obesity (Phase 2), BHV-1510 for advanced or metastatic epithelial tumors (Phase 2), and BHV-1530 for urothelial cancer (Phase 2). Preclinical programs target myasthenia gravis, immune-mediated diseases, pemphigus, membranous nephropathy, Graves' disease, type 1 diabetes, neurodegenerative diseases, and tinnitus.

Biohaven Ltd. is listed on the New York Stock Exchange (NYSE) under the ticker symbol BHVN. Its shares are traded in US Dollars (USD), as the company is headquartered in the United States and its primary listing is on a US exchange.

Biohaven Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on developing therapies for immunology, neuroscience, and oncology, leveraging biotechnology to create treatments for various diseases.

Biohaven Ltd. is headquartered in New Haven, Connecticut, United States. The company serves global markets, with a focus on developing treatments for immunology, neuroscience, and oncology indications worldwide. Its clinical trials and preclinical programs target diseases prevalent across multiple regions.

Biohaven's pipeline includes several key candidates: BHV-1300 (Phase 2) for Graves' disease and rheumatoid arthritis; BHV-1400 (Phase 2) for IgA nephropathy; BHV-1600 (Phase 1) for peripartum cardiomyopathy; BHV-8000 (Phase 3) for Parkinson's disease; Opakalim (Phase 3) for focal epilepsy; BHV-2100 (Phase 2) for pain disorders; BHV-2000 (Phase 2) for obesity; BHV-1510 (Phase 2) for advanced or metastatic epithelial tumors; and BHV-1530 (Phase 2) for urothelial cancer. Preclinical programs include BHV-1310 for myasthenia gravis, BHV-1320 for immune-mediated diseases, BHV-1450 for pemphigus, BHV-1420 for membranous nephropathy, BHV-1440 for Graves' disease and TED, BHV-6500 for type 1 diabetes, BHV-1490 for IgM neuropathy and Waldenstrom's, BHV-8100 for neurodegenerative diseases, and BHV-1955 for tinnitus.